The Wnt/beta -catenin pathway is a family of proteins that is implicated in many vital cellular functions like stem cell regeneration and organogenesis. Several intra-cellular signal transduction pathways are induced by Wnt, notably the Wnt/beta-catenin dependent pathway or canonical pathway and the non-canonical or beta-catenin-independent pathway, the latter includes the Wnt/Ca2+ and Planar Cell Polarity pathway (PCP). Wnt activation occurs at the intestinal crypt floor, and is critical to optimal maintenance of stem cells. Colorectal cancers show evidence of Wnt signaling pathway activation and this is associated with loss of function of the tumor regulator APC. Wnt activation has been observed in breast, lung, and hematopoietic malignancies and contributes to tumor recurrence. The Wnt pathway cross talks with the Notch and Sonic Hedgehog pathways, which has implications for therapeutic interventions in cancers.
Targeting the Wnt/beta-catenin Pathway in Cancer: Update on Effectors and Inhibitors Introduction
The Wnt family is a group of proteins implicated in many cellular functions: organ formation, stem cell renewal, and cell survival [1] . In humans, the Wnt family consists of cysteine rich glycoproteins that act as ligands for as many as fifteen receptors and co-receptors [2] . Extracellular Wnt can trigger varied intra-cellular signal transduction pathways, like the Wnt/beta-catenin dependent or canonical pathway and the beta-catenin-independent or noncanonical pathway (Figure1,2b) . Examples of the beta-catenin-independent pathway include the Wnt/Ca 2+ pathway as well as the Planar Cell Polarity pathway (PCP) [3] . The beta-catenindependent signaling pathway is triggered by the binding of Wnt ligand to the LRP-5/6 receptors (low-density lipoprotein receptor) and Frizzled receptors. This in turn activates Disheveled (DVL), causing recruitment of the complex (Axin, GSK-3 beta, CK1, APC) to the receptor. [4] [5] [6] . The Wnt -Frizzled-Axin -LRP-5/6complex sequesters cytosolic GSK-3 beta rendering it incapable of phosphorylating beta-catenin. There is accumulation of un-phosphorylated betacatenin in the cytosol which migrates to the nucleus, interacting there with T cellspecific factor(TCF)/ lymphoid enhancer-binding factor(LEF) and co-activators, like Pygopus (Pygo) and Bcl-9, to turn on the Wnt target genes such as c-Myc, cyclin D1 and Cdkn1a [6] .
Without Wnt, the beta-catenin in the cytosol undergoes phosphorylation by GSK-3 beta and CK1 and subsequent sequestration in the beta-catenin destruction complex, (APC, GSK-3 beta, CK1, Axin). This phosphorylated complex allows for the E3 ubiquitin ligase called beta-TrCP to attach to the beta-catenin at a binding site, that enhances its ubiquitination leading to subsequent proteasomal degradation [7] [8] (Figure 2a ). One of the Non-canonical Wnt pathways includes the PCP or Planar cell polarity pathway. This can be initiated by Wnt interaction with Frizzled receptors, with co-receptors RYK and ROR which control the activity of small GTPases such as RhoA that play a role in regulation of the remodeling of the cytoskeleton [8] (Figure 2b ). Wnt interaction with Frizzled leads to Dvl activation [8] . myosin and the Rho-associated kinase (ROCK) are activated by Rho GTPase, altering the mechanism of actin and cytoskeleton rearrangement. There is in tandem activation of Rac GTPase and activated Rac then stimulates JNK activity (c-Jun Nterminal kinase) [9] .
In the Wnt/ Ca 2+ pathway, activated by Wnt 5A, the frizzled FZD2 cleaves guanine nucleotide binding protein (G-protein), into protein beta/gamma subunits Gprotein alpha-t2 causing Ca 2+ to be released into the cytosol promoting differentiation in the neuronal system. Calcium activates CaMK II and Calmodulin, enhancing phosphorylation of Tcf/Lef (T-cell factor and lymphoid enhancer factor) thus suppressing the canonical Wnt pathway. The mechanisms by which Wnt5a can also interact via the canonical pathway are not completely mapped out though it is speculated that the LRP5 co-receptor is activated along with FZD4 and FZD5 receptors [10] [11] [12] [13] [14] .
Axin and APC-Negative regulators of Wnt
Axin serves as a scaffold protein recruiting GSK3β and CKIα (caspase kinase alpha) along with APC to form a complex with beta-catenin resulting in beta-catenin phosphorylation, ultimately causing its degradation. Axin also plays a key role in Wnt signaling initiation. PPPSP motifs on the cytoplasmic tail of LRP6 are phosphorylated upon Wnt activation. This in turn causes recruitment of Axin complexes to the membrane destabilizing beta-catenin complex in the cytoplasm. Axin is post translationally modified by phosphorylation/dephosphorylation. Without Wnt, Axin is phosphorylated, increasing its binding affinity with beta-catenin, leading to stabilization of Axin.
When Wnt stimulation is present, Axin is dephosphorylated, resulting in less binding with betacatenin and consequently Axin degradation [15] [16] [17] [18] .
APC supplies the framework for a destruction complex together with GSK3β and Axin that promotes phosphorylation and subsequent proteasomal degradation of beta-catenin. In addition, APC enhances export of beta-catenin from the nucleus, which reduces the amount of nuclear beta-catenin for interaction with TCF. Furthermore, APC can bind to beta-catenin, thereby blocking the beta-catenin interaction with TCF /LEF [19-20].
RNF43 and RSPO signaling modulation of Wnt
RNF43 (Ring finger protein 43) and the homolog ZNRF3 are transmembrane E3 ligases that dispose of the surface Wnt receptors and promote FZD receptor turnover. R-spondins or RSPO's are a group of proteins that together bind to the extracellular domains of LGR4/5 and RNF43/ ZNRF3, resulting in increased cell surface FZD receptors as this binding causes ubiquitination and clearance of RNF43/ZNRF3 [21, 22] .
Wnt and Notch signaling pathway cross-talk
It is thought that the Wnt-beta catenin pathways and Notch pathways interact for Drosophila wing development [23] . Importantly, the Notch target gene Hes1, which encodes a strong basic helix-loop-helix (bHLH) transcriptional repressor, is regulated by betacatenin-mediated Wnt signaling [24] . There is some evidence that direct interaction between beta-catenin and TCF activates Notch in colorectal cancer cells through regulation of Jagged1 expression. Βeta-catenin interaction with Notch-1 leads to decreased Notch-1 ubiquitination, causing Hes-1 expression to increase, which is associated with tumorigenesis.
The serine/threonine kinase GSK3β, is an important node in Wnt and Notch signaling crosstalk.
It mediates the phosphorylation of serine and threonine residues of the Notch intracellular domain (NICD-1), which in turn causes it to localize in the nucleus increasing its transcriptional activity and making it more stable [23] .
Loss of Notch-1 leads to activation of beta-catenin and increases the transcriptional activity of a beta-catenin-responsive reporter construct, suggesting that Notch dampens betacatenin-mediated responses to Wnt [24] . The non-canonical Wnt/Ca2 + pathway also interacts with Notch signaling. In the non-canonical Wnt/Ca2 + pathway, activation of CamKII by Wnt5a, induces the phosphorylation of the RBP-J-interacting corepressor SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) on serine 1407, resulting in increased promoter activity of a Notch-responsive gene [25] (Figure 2b ). Inhibitors of these effectors of the Wnt-beta catenin pathway are summarized in Table1.
Wnt-Sonic Hedgehog pathway cross-talk

Wnt in Cancers
Wnt pathway is upregulated in both MSI (microsatellite instable) and MSS (microsatellite stable) colorectal cancers [66] . Normally activated at the bottom of the intestinal crypts, Wnt is critical to cell repair and maintenance of stem cell functions. The primary mechanism of Wnt pathway activation is the loss of function of APC which functions as a negative regulator. Wnt/beta-catenin signaling is activated by truncated APC protein that negates destruction complex-mediated beta-catenin ubiquitination [66] .
RNF43 mutations lead to loss of function; they prevent removal of Wnt receptor in the intestinal crypt, thereby causing Wnt signaling activation [21] . They are found in over 18% of colorectal and endometrial cancers [67] . RSPO translocations are noted in 4-18% of patients with gastric, ovarian, and endometrial cancer and about 9% of colorectal cancers. Both RNF43 and R-spondin fusion are mutually exclusive with APC mutations; these alterations may predict for response to inhibitors of Wnt [68] .
More than half of breast cancers have activation of Wnt and that is associated with lower overall survival [69] . In a transgenic mouse model inhibition of beta-catenin-dependent signaling in ErbB2-derived cells impaired tumor initiation and metastasis additionally, treatment of ERBB2-overexpressing tumor cells with a selective beta-catenin/CBP inhibitor significantly decreased proliferation and ErbB2 expression [70] . There is an increase in active Wnt signaling in breast cancer stem cells which was confirmed by increased expression of activated betacatenin protein, both downstream targets AXIN2 and LEF1, and decreased expression of DKK1 protein [69] [70] .
In non-small cell lung cancer, there is evidence that lung cancer "stemness" is maintained by targeting the negative regulators of Wnt signaling for degradation, thereby increasing beta-catenin mediated Wnt activity [71] . Wnt ligands and receptors were shown to be expressed in the hematopoietic stem cells (HSC) and are found in the bone marrow microenvironment [72] . CML (chronic myeloid leukemia) patients in blast crisis have shown evidence of Wnt activation [73] . Wnt signaling plays a critical role in chemo-resistance in ovarian cancer and is involved in the maintenance and propagation of ovarian cancer stem cells [74] . Desmoid tumors are uncommon malignancies characterized by Wnt/β-catenin activation as the critical step in desmoid tumor formation with tumors almost always showing mutations of the beta-catenin gene or APC [75] . Table 2 ).
Wnt-signaling pathway inhibitors in clinical trials for cancer (
Inhibitors of the Wnt-Receptor Complex
Porcupine inhibitors (Figure 2a)
Porcupine (PORCN) is a membrane-bound O-acyltransferase (MBOAT) important for the secretion of Wnt ligands because it supplies the palmitoyl group to Wnt proteins, a crucial step for Wnt ligand secretion [76] .
The Porcupine-selective inhibitor LGK974 blocks Wnt signaling and tumor growth in vivo [40] . Head and neck squamous cell carcinoma (HNSCC) cell lines carrying NOTCH1 mutations that are inactivating are particularly sensitive to inhibition by LGK974 [77] . Porcupine is a Wnt pathway target that is amenable to inhibition while sparing Wnt-dependent tissues.
There are ongoing Phase 1/2 trials with LGK974 in metastatic colorectal and head and neck cancers with the characteristic mutations like Rnf43/Znrf3 [78] , but results are not yet reported (Table 2) . ETC-159 is a small molecule PORCN inhibitor with efficacy in preclinical models of RSPO-translocated colorectal cancer [79] . This molecule has been in Phase I trials since July 2015, with ten patients in the original cohort (9 Colorectal cancers and 1 renal) [80] . So far, there are no responses. One patient at 2 mg and 1 at 4 mg remained in the study in stable disease for 6 cycles ( Table 2. ).
Antibodies against Wnt family proteins
Specific Wnt ligands or receptors found to be over expressed in many tumors can also be targeted with agent's specific to these receptors. Monoclonal antibodies developed receptor (fused to a human IgG1 Fc fragment) [42] . There is concern for Wnt inhibition in bone and five patients had a doubling of a bone turnover marker β-C-terminal telopeptide returning to baseline levels after as single dose of zoledronic acid. There was stable disease for a period of over six months in two patients with desmoid tumors. 4 of 4 patients at 20 mg/kg with ≥1 on-study tumor assessment continue study with stable disease [82] . Three Phase 1b studies are currently in progress in hepatocellular cancer with sorafenib, pancreatic cancer in combined therapy with nab-paclitaxel and gemcitabine, and in combination with paclitaxel and carboplatin in ovarian cancer [83] (Table 2. ). 
Β-Catenin-Destruction Complex Inhibitors
Tankyrase inhibitors
Tankyrase belongs to the Poly (ADP-ribose) polymerases (PARPs) family. There are two isoforms of Tankyrase, Tankyrase 1 (PARP5a) and Tankyrase 2 (PARP5b) associated with the Wnt/beta-catenin signaling. Both these tankyrase isoforms increase the degradation of axin by the ubiquitin-proteasome pathway [85] . Tankyrase inhibitor, XAV939 [85] . Concerns of gastrointestinal toxicity have arisen in analysis of these inhibitors and further studies are needed [86] . There are currently no ongoing trials with Tankyrase inhibitors.
Disheveled inhibitors
Through the PDZ domain, disheveled (DVL) binds to the carboxyl terminal end of the FZD receptors, the common protein-interaction domain. NSC668036, FJ9, and 3289-8625 are some agents that block the FZD and DVL-PDZ interaction leading then to inhibition of the signal transduction pathway [34, 87] .
TCF/ beta-catenin Transcription Complex Inhibitors
There is great variation in Wnt signaling pathway mutations and there is a quest to find agents that can target the downstream effectors. Eight compounds were identified by highthroughput ELISA screening. PFK115-584 and CGP049090 are examples of these and can perturb the beta-catenin/TCF complex in a dose-dependent manner [88] . A major disadvantage is the non-selective nature of the inhibition of beta-catenin/TCF interaction.
Wnt co-activator antagonist
PRI-724 is a first-in-class small molecule antagonist that inhibits the interaction between beta-catenin and its transcriptional coactivator CBP (CREB-binding protein) [47] .
Preclinical studies of PRI-724 in pancreatic cancer suggest this agent can promote differentiation of chemotherapy-insensitive cancer stem cells and tumor-initiating cells, inhibit stroma formation, and decrease metastatic potential. Patients had progression following 1st-line treatment with FOLFIRINOX or FOLFOX chemotherapy. A 3+3 dose cohort escalation was done with gemcitabine (1000 mg/m2 on d1, 8, and 15 of 28 d cycle) and increasing doses of PRI-724 administered as a continuous infusion x7 days every other week. 20 patients were enrolled across 3 dose cohorts (doses of PRI-724 at 320, 640 and 905 mg/m2/d). 7/20 had Grade 3/4 adverse events. There was stable disease in 8 pts (40%) and 2 minor responses. 5 of 8 pts (62.5%) with elevated baseline CA19-9 levels showed a marker decline of 30%. Median PFS was 2 months (range, 0.7 to 7.7) [49] .
Wnt5a Mimetics
Primary breast carcinomas with low level of Wnt 5a have been found to have a lower disease-free survival suggesting a tumor suppressor role for Wnt 5 a. This has been borne out in hematopoietic, prostate, thyroid and colon cancers [89] . Conversely, in melanomas and gastric cancers Wnt 5a expression is associated with increased invasion and metastases [90] . Foxy-5 is a formulated hexapeptide that can mimic the properties of the Wnt5a molecule to impair cancer cell migration in vitro. A phase 1 study of Foxy-5 in patients with metastatic colon, breast, and prostate cancer shows no dose limiting toxicity and a phase 1b trial is ongoing [91] .
Gamma Secretase Inhibitors (GSI's)
There is growing evidence for cross talk between the Notch and Wnt pathways and in a recent study CD44+ CSCs (gastric cancer stem cells) showed high expression of HES-1 [92] . There is an ongoing Phase I/II study in patients with locally advanced or metastatic breast cancer of MK-0752with docetaxel ( Table 2) . PF-03084014 (Pfizer Inc., Groton, CT, USA) is a selective or Notch-sparing GSI or GS (gamma secretase) modulator [54] .PF-03084014 a small molecule GSI reduced tumor cell migration and mammosphere formation in vitro, reduced tumor cell self-renewal ability in vivo, and decreased mRNA expression of Notch target genes HES-1, HES-4, Notch-1, and HEY-2 in HCC (hepatocellular cancer)1599 xenograft tumors [94] .
A Phase 1 trial in triple negative breast cancer in combination with docetaxel had a partial response rate of 4/25(16%) and 9/25 (36%) with stable disease [54] . Gastrointestinal toxicity is a dose-limiting side-effect with Gamma secretase inhibitors. [53] [54] [55] [56] [57] [58] . Of interest, gamma secretase showed activity in desmoid tumors (5/9) had an objective response [95] .
Hedgehog Inhibitors
sFRP-1, a main target gene of the sonic hedgehog pathway, is involved in cross-talk between the hedgehog pathway and the Wnt pathway. Vismodegib is an FDA approved SMO inhibitor that binds directly to SMO; it is currently in use in advanced basal cell cancers. There are also ongoing phase 1/11 trials in cancers like pancreatic gastric, and prostate. Erismodegib (sonidegib) is another FDA-approved, orally bioavailable SMO antagonist used in advanced BCC and there are several ongoing Phase 1/11 trials in other malignancies [62] [63] [64] [65] . GLI transcription factors are the terminal effectors of the Shh-SMO signaling pathway and agents called GANTs (GLI antagonists), have shown activity in cell lines and xenografts and arsenic trioxide, a FDA approved drug for acute promyelocytic leukemia, has shown activity as an inhibitor of these transcription factors [96] .
Modulating Wnt in the clinical setting
Wnt-targeting therapies are varied and clinical experience nascent. Optimal use of these agents in the future will depend on matching the Wnt inhibitor with responsive alterations. As an example, Porcupine inhibitors act by blocking the secretion of Wnt ligands and may impact tumors carrying alterations e.g., RNF43 andLKB1, acting at the receptor level, in this case, the FZD receptors [78] . In contrast, APC truncating mutations are resistant to Porcupine inhibitors. since loss of APC may activate the pathway independent of Wnt ligands [79] . Tankyrase inhibitors target APC-mutated tumors, which constitute 80% of colorectal cancers, by stabilizing
Axin, but gastrointestinal toxicity may limit dose [86] .
Wnt inhibitors may work to eradicate the tumor resistant stem cell and thus may overcome resistance to conventional therapy including cytotoxic agents. Such an approach is currently being tested clinically for chronic myeloid leukemia with PRI-724 in combination with the kinase inhibitor Dasatinib [97] .
Sorafenib (Tyrosine kinase inhibitor) and refametinib (an MEK inhibitor) inactivate betacatenin signaling [98] . Since activating mutations in the Wnt/beta-catenin pathway is seen in many patients with HCC [99] , combination of sorafenib and refametinib may represent an alternative treatment for beta-catenin-dependent HCC [98] . In desmoid tumors, a phase 1 trial of PF-03084014, an oral Notch inhibitor showed that 5 of 9 patients had a partial response [95, 100] .
At first glance, the mechanism of action is not apparent because Notch is upstream of beta catenin. However, beta-catenin can directly express HES-1 and activate cell proliferation through it, and HES-1 is induced by Notch and decreased by Notch inhibitors [99] . Molecules such as Sulindac inhibit Wnt signaling, likely by blocking the PDZ domain of the Disheveled protein and have activity in APC-mutant colorectal cancers, reducing nuclear beta-catenin accumulation [51] .
Challenges to inhibiting the Wnt pathway
For the last 30 years targeting the Wnt signaling pathway has been an exciting target for inhibition. There is aberrant Wnt signaling in many cancers but thus far, no drugs have been approved to target this pathway, though there are recent clinical trials in a many hematologic and solid malignancies. One area of concern is the Wnt-beta catenin pathway's role in maintenance of stem cells and regeneration of tissues and organs [72] . There is legitimate concern that inhibition of the Wnt pathway may affect the normal Wnt dependent stem cell population, especially in areas of fast turnover like hair follicles and the gastro-intestinal tract. The preliminary experience with Tankyrase inhibitors suggests dose limiting gastrointestinal toxicity and this may limit use.
The Wnt pathway regulates many aspects of bone formation and agonists have been studied for promoting bone growth. An undesirable side effect of Wnt inhibition is increase in markers of bone turnover though in early trials this effect seems mitigated by single doses of a bisphosphonate [84] .
Additionally, an elucidation of the considerable cross talk between the cell signaling pathways will be crucial to designing an efficacious therapeutic approach. The focus of future trials should be using combination therapy with agents that affect these multiple pathways in solid and hematologic malignancies. 
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